This lay summary is intended to provide a general overview of the Children’s Oncology Group study ACCL05C1. It will provide information about the children that are eligible for this study and basic information regarding the specifics of the study. The informed consent and protocol contain the full details of the study. Those documents are available to you from your oncologist.

It is important to understand that participating in a clinical trial is entirely voluntary. The decision about whether or not to participate will not affect the care provided by the healthcare team in any way. You can find additional information about participation on clinical trials on Always discuss any questions that you may have with your healthcare team.

Brief Title: ACCL05C1: A study measuring hearing in patients receiving cisplatin chemotherapy.

Official Title: ACCL05C1: A group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy.

Trial Opening Date: May 7, 2007. A total of 150 eligible patients will take part in this study, and should take 2 years to enroll this number of patients.

General Patient Eligibility:

Please consult your doctor to determine whether your child may participate in this study.

Patient Age: 0-30 years of age

For patients:

Other major enrollment criteria:

Patients with the following may not be eligible:

General Background and Study Goal

When people are being treated for cancer they receive chemotherapy drugs that can cause hearing loss. It is standard care to have hearing tests on a regular basis to monitor for hearing loss. The standard type of hearing tests is called conventional audiometry. In this study, researchers want to learn more about evaluating for hearing loss by looking at conventional audiometry in different ways and by using two new types of hearing tests. These two new tests are called ultrahigh frequency (UHF) audiometry and otoacoustic emission and are more sensitive to measuring hearing loss than conventional tests.

The goals of this study are:

Summary of the Treatment

For patients receiving standard chemotherapy

For patients receiving a hematopoetic progenitor cell transplant

Contact Information

Your child’s oncologist is the best source for further information. Physicians with eligible patients should refer questions to the principal investigator:

Principal Investigator Lillian Sung, MD, PhD
Division of Haematology/Oncology
The Hospital for Sick Children
555 University Avenue
Toronto, Ontario M5G 1X8
Phone: (416) 813-5287
Fax: (416) 813-5979
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

© The Children's Oncology Group
The information and content provided on this website is made available for informational purposes only for children and their families affected by cancer. While the Children's Oncology Group strives to provide accurate and up-to-date information, the information may be out of date or incomplete in certain respects. Please do not rely on this information and seek the care of a qualified medical professional if you have questions regarding a specific medical condition, disease, diagnosis or symptom. The information and content presented herein is not intended to replace the independent clinical judgement, medical advice, screening, health counseling, or other intervention performed by your (or your child's) health care provider. Please contact "911" or your emergency services if this is a health emergency. No endorsement of any specific tests, products, or procedures is made herein.